The overall goal of the Imaging Core is to develop, implement, optimize, and validate quantitative surrogate biomarkers of tumor treatment response. This Core will be dedicated to providing scientific and technical resources and support for non-invasive imaging of small animal models of cancer in vivo] and is fundamental to the success of three of the four projects described in this application. Projects supported by the Imaging Core are directed at employing existing as well as novel, targeted therapies which will elicit molecular signatures that can be imaged via optical, SPECT, and PET methods and then complemented with the (downstream) physiological information obtained from ultrasound, MRI, and CT. In particular, Project 1 (PI: Arteaga) and Project 3 (PI: Pietenpol) will employ noninvasive molecular imaging metrics (FLT-PET, FDG-PET, Annexin-V microSPECT and optical) to assess tumor cell proliferation, glucose metabolism, and apoptosis in response to novel therapies. Project 2 (PI: Mundy) will employ noninvasive molecular imaging metrics (bioluminescence, fluorescence, and microSPECT/CT) to track breast cancer metastases to bone and assess bone quality. In addition to providing the methods required by SPORE projects, the Imaging Core will develop techniques that can augment these studies as well as support developmental pilot projects. The equipment and personnel needed to support research by investigators from within the SPORE will be provided by the Center for Small Animal Imaging (CSAI) (see Resources)). Funds obtained through the SPORE will support collaborations with expert imaging science faculty for the development and implementation of cutting edge imaging protocols;support for imaging system operators and technical staff who will handle animal preparation and monitoring as well as operate the instruments;support for data analysis and for quantitative image analysis customized to specific applications, including the coregistration and integration of multiple imaging modalities, histology and proteomics. 1. Provide non-invasive imaging metrics of tumor initiation, progression and treatment response to investigators in the Vanderbilt Breast SPORE. 2. Provide collaborations with expert imaging science faculty for the implementation of cutting edge imaging protocols to address each investigators goals. The Imaging Core will support experts in nuclear, optical, MRI, CT, and ultrasound imaging. 3. Provide support for data analysis and for quantitative image analysis customized to specific applications, including the co-registration and integration of multiple imaging modalities, histology and proteomics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA098131-09
Application #
8270591
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
9
Fiscal Year
2011
Total Cost
$148,670
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Santos Guasch, Gabriela L; Beeler, J Scott; Marshall, Clayton B et al. (2018) p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. iScience 8:236-249
Croessmann, Sarah; Sheehan, Jonathan H; Lee, Kyung-Min et al. (2018) PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K? Inhibitors. Clin Cancer Res 24:1426-1435
Elion, David L; Cook, Rebecca S (2018) Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. Oncotarget 9:29007-29017
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194
Luo, Na; Nixon, Mellissa J; Gonzalez-Ericsson, Paula I et al. (2018) DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun 9:248
Sudhan, Dhivya R; Schwarz, Luis J; Guerrero-Zotano, Angel et al. (2018) Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. Clin Cancer Res :
Werfel, Thomas A; Wang, Shan; Jackson, Meredith A et al. (2018) Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Cancer Res 78:1845-1858
Zhao, Shilin; Li, Chung-I; Guo, Yan et al. (2018) RnaSeqSampleSize: real data based sample size estimation for RNA sequencing. BMC Bioinformatics 19:191
Jovanovi?, Bojana; Sheng, Quanhu; Seitz, Robert S et al. (2017) Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. BMC Cancer 17:241

Showing the most recent 10 out of 341 publications